BioLegend

Mission Bio Launches Sample Multiplexing for Tapestri to Unlock Critical Single-Cell Insights for Oncology and Genome Editing Markets

Retrieved on: 
Thursday, April 4, 2024
Health, Hospitals, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, PCR, Mutation, B cell, DNA, BioLegend, Medicine, Cancer, Hospital, Drug development, Bone marrow, Mission, AOCS, Pathology, Vaccine

Mission Bio , a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform.

Key Points: 
  • Mission Bio , a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform.
  • Combining multiple samples into a single experiment will help lower this barrier to entry for academic researchers and de-risk the adoption for biopharma.
  • Sample multiplexing by genotyping, unique to Tapestri, uses the genetic information of the relevant variants obtained by bulk next-generation sequencing to distinguish samples.
  • Mission Bio’s multiplexing capabilities make single-cell technology more accessible to the biomedical community and has the potential to dramatically impact patient care in the future.”
    For more information about Tapestri, please visit www.missionbio.com .

Labroots to Host the 6th Annual Bioprocessing Virtual Event Series on April 3rd, 2024

Retrieved on: 
Thursday, March 28, 2024
University at Albany, SUNY, State university system, Analytic, Sartorius, Research, Downstream processing, Science News, BioLegend, Bioprocess, University, Drug discovery, Carbohydrate, Immortalised cell line, Biology, Quality, Labroots, Cell, Molecular biology, Eppendorf

YORBA LINDA, Calif., March 28, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific networking website and producer of educational virtual events and webinars, is thrilled to announce the 6th Annual Bioprocessing Virtual Event Series, scheduled for April 3rd, 2024. This free, day-long online event will bring together experts and enthusiasts from around the globe to delve into the latest advancements and topics in bioprocessing.

Key Points: 
  • YORBA LINDA, Calif., March 28, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific networking website and producer of educational virtual events and webinars, is thrilled to announce the 6th Annual Bioprocessing Virtual Event Series , scheduled for April 3rd, 2024.
  • This free, day-long online event will bring together experts and enthusiasts from around the globe to delve into the latest advancements and topics in bioprocessing.
  • Labroots leverages the Chati virtual event platform to offer an interactive, immersive educational digital experience.
  • Participants can use the official hashtag #LRbioprocessing to follow the conversation and connect with other members in the Bioprocessing community!

Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend

Retrieved on: 
Monday, January 8, 2024
Pseudogene, RNA, Biomedical Research, Protein, NIPT, Antibody, Telecommunications, Workflow, Research, DNA, SAN, Methylation, Biomarker, Infection, BioLegend, Fine chemical

This marks the first instance of an early access version of RAPTOR with Pleno’s groundbreaking multi-omic readout technology called Hypercoding ™ verified outside of its development lab.

Key Points: 
  • This marks the first instance of an early access version of RAPTOR with Pleno’s groundbreaking multi-omic readout technology called Hypercoding ™ verified outside of its development lab.
  • The RAPTOR instrument platform utilizes Hypercoding to detect these biomarkers rapidly and efficiently at a sample throughput that is scalable from a couple dozen samples to 96.
  • To this end, Pleno and BioLegend have collaborated to integrate their technologies, facilitating a streamlined approach for customers to enable multi-omic content.
  • “We are extremely proud to see the first of our RAPTOR instruments leave the nest,” said Pieter van Rooyen, founder and CEO of Pleno.

Breast Cancer Multiomics: Unified Insights in Tumor Heterogeneity, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, December 12, 2023
WGS, PST, ASCP, Whole genome sequencing, IDT, Gold, Disease, Breast cancer, Informatics, Transcriptome, Patient, CNV, Ductal carcinoma, MB, EST, Doctor of Philosophy, RNA-Seq, BioLegend, Cell, Vaccine

TORONTO, Dec. 12, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar exploring a novel single-cell method for breast cancer multiomics, linking genetic variations, copy number changes and gene expressions with focused panels. While the information obtained from whole genome sequencing (WGS) studies is a clear gold standard for discovery-based sequencing, current sequencing costs and informatics challenges frequently diminish WGS usage. Instead, applications focus on exonic spaces, particularly druggable targets. The majority of these are small, focused panels — resulting in a significant resolution gap between comprehensive WGS and these focal panels.

Key Points: 
  • In this free webinar, explore a new method detailing genetic insights into breast cancer, enabling precise assessment of variations, gene expressions and targeted proteins at a single-cell level.
  • TORONTO, Dec. 12, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar exploring a novel single-cell method for breast cancer multiomics, linking genetic variations, copy number changes and gene expressions with focused panels.
  • In this webinar, the featured speaker describes the utility of the IDT v2 exome hybrid capture after ResolveOME single-cell workflow in a cohort of cells derived from breast cancer patients.
  • Join this webinar to explore a new method detailing genetic insights into breast cancer, enabling precise assessment of variations, gene expressions and targeted proteins at a single-cell level.

Telesis Bio Appoints William J. Kullback Chief Financial Officer

Retrieved on: 
Tuesday, August 29, 2023
Treasury, DNA, Telesis, State university system, Buffalo, MBA, Doctor of Philosophy, Sale, Accounting, Synthetic biology, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, PerkinElmer, Acquisition, SAN, CFO, Financial management, NYSE, BioLegend, Management

SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023.

Key Points: 
  • SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023.
  • As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions.
  • “Bill’s deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to help lead us through the next phase of the Company’s growth,” said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio.
  • Before joining BioLegend in 2017, Mr. Kullback served as Chief Financial Officer of Lombard Medical, Inc., a medical device company, from 2014 to 2017, prior to its acquisition by MicroPort Scientific Corporation, a Shanghai, China based medical device group.

Flow Cytometry Market worth $7.0 billion | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023
BioLegend, PlayStation Portable system software, Disease, Drug development, Drug discovery, Cancer research, Sartorius AG, Personalized medicine, Functional analysis, Research, Medicine, Agilent Technologies, Cell, Automation, Miniaturization, Disulfiram-like drug, Danaher Corporation, Transplant, Neuroscience, Acquisition, Laboratory, Machine learning, Microbiology, Flow cytometry, Apoptosis, Cell cycle, Hematology, Miltenyi Biotec, Luminex Corporation, SPS, Robotics, AI, B cell, Sony, Behavior, Sysmex Corporation, Computer data storage, Mobile phone, Pharmaceutical industry, Medical imaging

In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.

Key Points: 
  • In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.
  • In May 2023, Sysmex launched Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
  • Personalized Medicine: Flow cytometry contributes to personalized medicine by enabling tailored treatments based on individual patient profiles and disease characteristics.
  • These pointers highlight the multifaceted advantages of flow cytometry, making it an indispensable tool in scientific research, clinical diagnostics, and healthcare innovation.

Flow Cytometry Market worth $7.0 billion | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023
BioLegend, PlayStation Portable system software, Disease, Drug development, Drug discovery, Cancer research, Sartorius AG, Personalized medicine, Functional analysis, Research, Medicine, Agilent Technologies, Cell, Automation, Miniaturization, Disulfiram-like drug, Danaher Corporation, Transplant, Neuroscience, Acquisition, Laboratory, Machine learning, Microbiology, Flow cytometry, Apoptosis, Cell cycle, Hematology, Miltenyi Biotec, Luminex Corporation, SPS, Robotics, AI, B cell, Sony, Behavior, Sysmex Corporation, Computer data storage, Mobile phone, Pharmaceutical industry, Medical imaging

In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.

Key Points: 
  • In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.
  • In May 2023, Sysmex launched Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
  • Personalized Medicine: Flow cytometry contributes to personalized medicine by enabling tailored treatments based on individual patient profiles and disease characteristics.
  • These pointers highlight the multifaceted advantages of flow cytometry, making it an indispensable tool in scientific research, clinical diagnostics, and healthcare innovation.

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Retrieved on: 
Monday, June 12, 2023
Heart, BioLegend, Executive, AIM, Failure, ADR, Policy, Net operating assets, Audit committee, Disclosure, EGM, ERP, History, Antibody, Churn, Massage, CFOS, PGIP, Enterprise resource planning, ITGC, Accounting, Risk, CFO, Growth, EPS, Citibank, Letter, Environment, NYSE, Remuneration, Benchmarking, Chairperson, Management, Security (finance), Audit, Bank, Cryptocurrency, Risk management, Abcam

The full text of the letter follows:

Key Points: 
  • The full text of the letter follows:
    As the Founder and 6.3% shareholder in Abcam plc (“Abcam” or the “Company”), I am dedicated to helping restore Abcam’s financial and operational performance and to driving value for all shareholders.
  • I believe that management miscues can be easily fixed positioning Abcam to deliver value to shareholders in short, medium and long term.
  • This letter details what has gone wrong at Abcam and why change is desperately needed.
  • I can support and constructively challenge the current management team, lead the Board appropriately and increase value for all shareholders.

Historic $100 Million Gift to Brigham and Women’s Hospital to Establish Institute of Immunology and Inflammation of the Brigham, Massachusetts General Hospital, and Harvard Medical School

Retrieved on: 
Wednesday, May 10, 2023
University, Biotechnology, Education, Health, Philanthropy, General Health, Research, Hospitals, Surgery, Foundation, Science, Inflammation, Allergy, MGH, Integrative Biology, Vijay Kuchroo, MSHA, COVID-19, Ageing, Cancer, Doctor of Philosophy, Harvard University, Harvard Medical School, Student, Protein, Computation, DSM-IV codes, Head, Patient, Mass, Mass General Brigham, Faculty, United Kingdom, Diagnosis, Hospital, New institutional economics, Immunology, B cell, HMS, Massachusetts General Hospital, DVM, Disease, BioLegend, Management, Pharmaceutical industry, Vaccine, Brigham, MD

The landmark gift—the largest in the Brigham’s history—will establish The Gene Lay Institute of Immunology and Inflammation of Brigham and Women’s Hospital, Massachusetts General Hospital (MGH), also a founding member of Mass General Brigham, and Harvard Medical School (HMS).

Key Points: 
  • The landmark gift—the largest in the Brigham’s history—will establish The Gene Lay Institute of Immunology and Inflammation of Brigham and Women’s Hospital, Massachusetts General Hospital (MGH), also a founding member of Mass General Brigham, and Harvard Medical School (HMS).
  • Vijay Kuchroo, DVM, PhD, an immunologist and principal investigator at the Brigham, will serve as inaugural director of the institute, which will be located at and administered by the Brigham.
  • “And I’ve had a longstanding relationship with and respect for the scientists in the Harvard medical community, who played an instrumental role in my career.
  • In addition, the Gene Lay Institute will provide substantial training opportunities for students and fellows to support immunology innovators of the future.

Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

Retrieved on: 
Tuesday, May 9, 2023
Science, Software, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Technology, Omni, Intellectual property, Failure, Risk, COVID-19, Omni International Jet Trading, Form 10-K, Sale, Horizon Discovery, Name, PerkinElmer, Webcast, Diagnosis, Government, Security (finance), Annual report, Social media, Automation, BioLegend, Pharmaceutical industry

Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere.

Key Points: 
  • Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere.
  • Born from two words, “revolutionize” (rev) and “vita” (vit) meaning “life” in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure.
  • “We’re a translational company in the sense that our capabilities facilitate decision making between research and clinical customers,” remarked Singh.
  • The Company will trade under its new name and the stock ticker symbol "RVTY” at market open on May 16, 2023.